… ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs In … to focus exclusively on the development of the Axiomer ® RNA editing technology platform across multiple therapeutic … sepofarsen and will now focus exclusively on its Axiomer ® RNA-editing technology platform. Following the results from …
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas
… Lilly and ProQR to Expand RNA Editing Collaboration New agreement supports the … in September 2021, applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders of the liver and …
… Leading Intellectual Property Estate for ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, … US patent No. 11,781,134 that relates to a method for RNA editing. Key claims in this patent pertain to use of any …
… ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 LEIDEN, Netherlands … RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today announced a …
… Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 Platform demonstrates … RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted key …
